Pilot trial of a novel two-step therapy protocol using nebulized tranexamic acid and recombinant factor VIIa in children with intractable diffuse alveolar hemorrhage
BACKGROUND AND OBJECTIVES: Diffuse alveolar hemorrhage (DAH) is a life threatening condition with very limited, often unsuccessful, therapeutic options. This study aimed at exploring the feasibility and efficacy of nebulized tranexamic acid TXA (n-TXA) and nebulized recombinant factor VIIa (n-rFVIIa...
Main Authors: | Hind Bafaqih, May Chehab, Suliman Almohaimeed, Farah Thabet, Abdulrahman Alhejaily, Mohammed AlShahrani, Mohammed A. Zolaly, Abeer A. Abdelmoneim, Ehab S. Abd El-Moneim |
---|---|
Format: | Article |
Language: | English |
Published: |
King Faisal Specialist Hospital and Research Centre
2015-05-01
|
Series: | Annals of Saudi Medicine |
Online Access: | https://www.annsaudimed.net/doi/full/10.5144/0256-4947.2015.231 |
Similar Items
-
Nebulized tranexamic acid for recurring hemoptysis in critically ill patients: case series
by: Fatimah Alabdrabalnabi, et al.
Published: (2020-08-01) -
Successful Treatment of Intractable Hemothorax with Recombinant Factor VIIa in a Nonhemophilic Patient
by: Yu-Feng Wei, et al.
Published: (2006-01-01) -
Diffuse alveolar hemorrhage and recombinant factor VIIa treatment in pediatric patients
by: Jeong A Park
Published: (2016-03-01) -
Age-related changes in biochemical bone profile in thalassemic children
by: Ehab S. Abd El-Moneim, et al.
Published: (2018-04-01) -
Use of nebulized tranexamic acid in adult and pediatric post-tonsillectomy hemorrhage
by: Angela Cao, et al.
Published: (2022-06-01)